SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma

Published:2024-05 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Bennett Rory,Dickinson Michael^ORCID

Publisher

Elsevier BV

Reference93 articles.

1. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Revised;Swerdlow,2017

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

3. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma;Tilly;N Engl J Med,2022

4. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA;Sehn;J Hematol Oncol,2020

5. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;JCO,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP